IPN-60090
- CAS No.
- 1853164-83-6
- Chemical Name:
- IPN-60090
- Synonyms
- IACS-6274;GLS1-IN-1;IPN-60090;IACS-006274;IPN60090,IPN-60090;IACS-6274(IPN60090);IPN-60090 ( IACS-6274);IPN60090, 10 mM in DMSO;1-[(2R)-4-[6-[[2-[4-(3,3-difluorocyclobutoxy)-6-methyl-2-pyridyl]acetyl]amino]pyridazin-3-yl]-2-fluoro-butyl]-N-methyl-triazole-4-carboxamide;2-Pyridineacetamide, 4-[(3,3-difluorocyclobutyl)oxy]-N-[6-[(3R)-3-fluoro-4-[4-[(methylamino)carbonyl]-1H-1,2,3-triazol-1-yl]butyl]-3-pyridazinyl]-6-methyl-
- CBNumber:
- CB77244426
- Molecular Formula:
- C24H27F3N8O3
- Molecular Weight:
- 532.52
- MDL Number:
- MFCD33023198
- MOL File:
- 1853164-83-6.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Density | 1.47±0.1 g/cm3(Predicted) |
|---|---|
| storage temp. | Store at -20°C |
| solubility | DMSO : 31.43 mg/mL (59.02 mM; Need ultrasonic) |
| pka | 11.74±0.70(Predicted) |
| form | Solid |
| color | Pink to red |
| FDA UNII | O6ZT4D087I |
IPN-60090 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 35855 | IPN60090 ≥98% | 1853164-83-6 | 1mg | $197 | 2026-04-30 | Buy |
| Cayman Chemical | 35855 | IPN60090 ≥98% | 1853164-83-6 | 5mg | $493 | 2026-04-30 | Buy |
| Biosynth | DZC16483 | IPN-60090 | 1853164-83-6 | 1mg | $250 | 2026-06-04 | Buy |
| Biosynth | DZC16483 | IPN-60090 | 1853164-83-6 | 5mg | $590.6 | 2026-06-04 | Buy |
| Biosynth | DZC16483 | IPN-60090 | 1853164-83-6 | 10mg | $944.9 | 2026-06-04 | Buy |
IPN-60090 Chemical Properties, Uses, Production
Uses
IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers[1][2].
in vivo
IPN60090 (3 mg/kg for i.v.; 10 mg/kg for p.o.) has excellent pharmacokinetic properties, with CL=4.1 mL/min/kg, t1/2=1 hour, Cmax=19 μM, F%=89%[2].
IPN-60090 (oral administration; 100 mg/kg; twice daily; 30 days) shows similar efficacy and target engagement to CB-839 (HY-12248) dosed orally at 250 mg/kg twice daily. And the 100 mg/kg BID dose of IPN-60090 is a tolerated dose for the following model study[2].IPN-60090 (oral administration; 100 mg/kg; twice daily; 30 days; monotherapy or in combination with TAK228 (HY-13328)) causes tumor growth inhibition. IPN-60090 alone demonstrates robust in vivo target engagement in a dose-dependent manner. The glutamate/glutamine ratios and the free plasma concentrations of IPN-60090 at 4 hours post-dose on both day 4 and day 28 are all decreased[2]. Furthermore, IPN-60090 in combination with TAK228 strongly causes an 85% tumor growth inhibition, IPN-60090 alone causes a 28% tumor growth inhibition in vivo[2].
| Animal Model: | Female CD-1 mice[2] |
| Dosage: | 3 mg/kg for i.v.; 10 mg/kg for p.o. (Pharmacokinetic Analysis) |
| Administration: | Intravenous injection and oral administration |
| Result: | CL (4.1 mL/min/kg), t1/2 (1 hour) for i.v.; Cmax (19 μM), F% (89%) for p.o.. |
| Animal Model: | Ru337 non-small cell lung cancer patient-derived xenograft (PDX) subcutaneous mouse model as monotherapy or in combination[2] |
| Dosage: | 100 mg/kg |
| Administration: | Oral administration; 100 mg/kg; twice daily; 30 days; monotherapy or in combination with TAK228 |
| Result: | Exhibited an improvement in the combination regimen group over either single agent. |
References
[1] Maria Emilia Di Francesco, et al. Gls1 inhibitors for treating disease. WO2016004404A2.
[2] Michael J Soth, et al. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem. 2020 Nov 12;63(21):12957-12977. DOI:10.1021/acs.jmedchem.0c01398
IPN-60090 Preparation Products And Raw materials
Raw materials
Preparation Products
IPN-60090 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 18149758185 18149758185 | sales-cpd@caerulumpharma.com | China | 3493 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Chunchuang (Wuhan) Technology Co., Ltd | 15727060112 | yutianchun2007@126.com | China | 9867 | 58 |
| Wuhan Topule | +86-02787215551 19945035818 | 2936752263@qq.com | China | 7983 | 58 |
| Hubei Kele Fine Chemical Co., Ltd | 027-59101668 19945030958 | 2223443625@qq.com | China | 7998 | 58 |
| Kaifeng Mingren Pharmaceutical Co.,LTD | 0371-65741762 | sales@hasunny.com | China | 2377 | 58 |
| InvivoChem | 13549236410 | sales@invivochem.cn | China | 6745 | 58 |
| Wuhan Shanhai Zhihe Biotechnology Co., Ltd. | 17771424646 | shoubull@126.com | China | 892 | 58 |
1853164-83-6 (IPN-60090) Related Search:
1of2
